Sam Altman’s Life Extension Guy Warns of Injections That Cause Wild Tumor Growth

In a daring move, OpenAI CEO Sam Altman is investing a staggering $180 million in Retro Biosciences, a startup aiming to discover innovative methods to extend human longevity. Retro Biosciences utilizes a risky approach by concurrently investigating five diverse areas of anti-aging science. Despite the hefty investment and optimistic ambitions, the research is fraught with challenges, such as reprogramming damaged cells and rejuvenating the immune system. Furthermore, the potential life-extending therapies are still in their infancy, and there are significant risks associated with failure. Notably, Altman’s investment in anti-aging research aligns with a trend among billionaires, including Jeff Bezos and Peter Thiel, to wager large sums on anti-aging endeavors. Despite the financial support, Retro Biosciences acknowledges the need for additional investors and possibly going public to realize their ambitious goals.